• Myriad Genetics Inc MYGN.OQ reported quarterly adjusted earnings of 4 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 3 cents. The mean expectation of fourteen analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents tozero cents per share.

• Revenue fell 0.4% to $209.80 million from a year ago; analysts expected $207.37 million.

• Myriad Genetics Inc's reported EPS for the quarter was a loss of 8 cents​.

• The company reported a quarterly loss of $7.9 million.

• Myriad Genetics Inc shares had fallen by 30.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 40% in the last three months.​

• In the last 30 days, seven analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 7 "hold" and 3 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Myriad Genetics Inc is $7.00, about 37.4% above its last closing price of $4.38

This summary was machine generated from LSEG data February 23 at 10:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)